2-Amino-5-(diaminomethylideneamino)hexanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Amino-5-(diaminomethylideneamino)hexanoic acid
• 化学式: C₇H₁₆N₄O₂
• 分子量: 188.23
• InChiKey: AATIXZODJZMQQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.8
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  128
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• [EN] CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS<br/>[FR] PEPTIDES CYCLIQUES POUR LA PROTECTION CONTRE LE VIRUS RESPIRATOIRE SYNCYTIAL
  申请人：VIROMETIX AG

  公开号：WO2018229156A1

  公开（公告）日：2018-12-20

  The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus. In particular, the present invention relates to a cyclic peptide, wherein said cyclic peptide comprises an amino acid sequence (I), wherein said amino acid sequence (I) comprises the following amino acid sequence: X1-X2-X3-C4-X5-X6-X7-C8-X9-X10-X11-P12-I13-T14-N15-D16-Q17-K18-K19-L20-C21- X22-X23-X24-C25-X26-X27-X28-X29-X30 (SEQ ID NO: 1), wherein X1, X2, X3, X5, X6, X7, X9, X10, X11, X22, X23, X24, X26, X27, X28 and X29 are independently of each other an amino acid; C4, C8, C21 and C25 are independently of each other cysteine; P12 is proline; I13 is isoleucine; T14 is threonine; N15 is asparagine; D16 is aspartic acid; Q17 is glutamine; K18 and K19 are independently of each other lysine; L20 is leucine; and X30 is an amino acid or a deletion, wherein said cysteines C4 and C25 form a first disulfide bond and said cysteines C8 and C21 form a second disulfide bond.

  本发明涉及一种环肽，一种包含所述环肽和脂肽肽基的结合物，一束所述结合物，一种合成的类病毒颗粒，其中包括至少一个结合物束以及包含它们的制药组合物。本发明还涉及该环肽，该结合物，该结合物束，该合成的类病毒颗粒和该制药组合物作为药物的用途，优选用于预防传染病或降低传染病风险的方法，更优选用于预防或降低与呼吸道合胞病毒相关或由其引起的传染病的方法。特别地，本发明涉及一种环肽，其中所述环肽包括氨基酸序列(I)，其中所述氨基酸序列(I)包括以下氨基酸序列：X1-X2-X3-C4-X5-X6-X7-C8-X9-X10-X11-P12-I13-T14-N15-D16-Q17-K18-K19-L20-C21-X22-X23-X24-C25-X26-X27-X28-X29-X30(SEQ ID NO:1)，其中X1、X2、X3、X5、X6、X7、X9、X10、X11、X22、X23、X24、X26、X27、X28和X29分别是氨基酸；C4、C8、C21和C25分别是半胱氨酸；P12是脯氨酸；I13是异亮氨酸；T14是苏氨酸；N15是天冬氨酸；D16是天冬酸；Q17是谷氨酰胺；K18和K19分别是赖氨酸；L20是亮氨酸；X30是氨基酸或缺失，其中所述半胱氨酸C4和C25形成第一二硫键，所述半胱氨酸C8和C21形成第二二硫键。
• C-DI-GMP BINDING PEPTIDES
  申请人：Universität Basel

  公开号：EP3335720A1

  公开（公告）日：2018-06-20

  The present invention is directed to a peptide comprising at least one amino acid sequence (I), wherein said amino acid sequence (I) comprises, preferably consists of, the amino sequence D1-X2-X3-X4-X5-X6-X7-X8-X9-Y10-X11-G12-X13-R14-R15-R16-X17-X18-D19, a composition and a pharmaceutical composition comprising the peptide of the invention, the peptide of the invention for use as a medicament in the treatment or prevention of a disease, non-medical use of the peptide of the invention, and a nucleic acid encoding the peptide of the invention.

  本发明涉及一种包含至少一个氨基酸序列(I)的多肽，其中所述氨基酸序列(I)包含，优选由氨基酸序列D1-X2-X3-X4-X5-X6-X7-X8-X9-Y10-X11-G12-X13-R14-R15-R16-X17-X18-D19组成、包含本发明多肽的组合物和药物组合物，本发明多肽用作治疗或预防疾病的药物，本发明多肽的非医疗用途，以及编码本发明多肽的核酸。
• Arginine improves polymerase storage stability
  申请人：Bio-Rad Laboratories, Inc.

  公开号：US10053676B2

  公开（公告）日：2018-08-21

  Liquid storage solutions comprising polymerases are provided.

  提供了包含聚合酶的液体储存溶液。
• TUMOR TARGETING AGENTS AND USES THEREOF
  申请人：Karyon OY

  公开号：EP1549667A1

  公开（公告）日：2005-07-06
• DIAGNOSTIC AND THERAPEUTIC AGENTS
  申请人：Karyon-CTT Ltd

  公开号：EP1874800A1

  公开（公告）日：2008-01-09